ZOMETA® Patient Lung Cancer Case Study and Medical Profile – Initial Diagnosis
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Anthony P.
  • Aged 64 years
  • Retired auto mechanic
  • Quit smoking 10 years ago
Page  1 2

Initial diagnosis and treatment

  • Anthony presented with cough, fatigue, lower back pain, and pain in his left leg that caused him to limp
  • Bronchoscopic biopsy revealed nonsquamous nonsmall cell lung cancer in the upper right lobe
  • Bone scan showed a metastatic lesion in the proximal left femur
  • Anthony has an ECOG performance status of 1




Page  1 2